Skip to main content

Advertisement

SpringerLink
Log in

BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid

  • Concise Communication
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Bullous pemphigoid (BP) is an autoimmune bullous disease characterized by autoantibody production against BP180 and BP230. Two scoring systems have been validated for BP including: Bullous Pemphigoid Disease Area Index (BPDAI) and Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). In this study, we investigated correlations between both scoring systems and either anti-BP180 NC16A or anti-BP230 values. BPDAI and ABSIS were used to measure disease activity in 95 BP patients at Razi Hospital in Tehran, Iran. ELISA was performed on patient sera to identify any significant relationship between anti-BP180 NC16A/anti-BP230 values and BP disease activity. The two scores showed a strong correlation (ρ = 0.73; p value < 0.0001). Anti-BP180 NC16A values correlated with BPDAI (ρ = 0.49, p value = 0.0001), ABSIS (ρ = 0.47, p value < 0.0001), and BPDAI-Pruritus scores (ρ = 0.29, p value < 0.005). There was a strong correlation between anti-BP180 NC16A values and the ABSIS Skin score (ρ = 0.58, p value < 0.0001), and a moderate correlation with erosion/blister BPDAI score (ρ = 0.48, p value < 0.001) and urticaria/erythema BPDAI score (ρ = 0.27, p value = 0.009). Anti-BP230 values did not demonstrate any relationship with either scores or their subcomponents. Both scoring systems demonstrated moderate validity. Mucosal components did not show any correlation with anti-BP antibodies and are disproportionately presented in both BP scoring tools.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bernard P, Bedane C, Bonnetblanc JM (1997) Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol 136:694–698

    Article  CAS  PubMed  Google Scholar 

  2. Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, Wojnarowska F, Steven SR, Chen M, Fairley JA, Woudley DT, Miller SD, Gordon KB (1998) Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 110:103–109

    Article  CAS  PubMed  Google Scholar 

  3. Daneshpazhooh M, Chams-Davatchi C, Payandemehr P, Nassiri S, Valikhani M, Safai-Naraghi Z (2012) Spectrum of autoimmune bullous diseases in Iran: a 10-year review. Int J Dermatol 51:35–41

    Article  PubMed  Google Scholar 

  4. Di Zenzo G, Thoma-Uszynski S, Calabresi V, Fontao L, Hofmann SC, Lacour JP, Sera F, Bruckner-Tuderman L, Zambruno G, Borradori L, Hertl M (2011) Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol 131:2271–2280

    Article  PubMed  Google Scholar 

  5. Hashimoto T, Ohzono A, Teye K et al (2017) Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid. Br J Dermatol 177(1):141–151

    Article  CAS  PubMed  Google Scholar 

  6. Ishiura N, Fujimoto M, Watanabe R, Nakashima H, Kuwano Y, Yazawa N, Echigo T, Okochi H, Tamaki K (2008) Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 49:153–161

    Article  CAS  PubMed  Google Scholar 

  7. Lee EH, Kim YH, Kim S, Kim SE, Kim SC (2012) Usefulness of enzyme-linked immunosorbent assay using recombinant BP180 and BP230 for serodiagnosis and monitoring disease activity of bullous pemphigoid. Ann Dermatol 24:45–55

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Le Sache-de Peufeilhoux L, Ingen-Housz-Oro S, Hue S, Sbidian E, Valeyrie-Allanore L, Ortonne N, Roujeau JC, Wolkenstein P, Chosidow O, André C (2012) The value of BP230 enzyme-linked immunosorbent assay in the diagnosis and immunological follow-up of bullous pemphigoid. Dermatology 224:154–159

    Article  PubMed  Google Scholar 

  9. Levy-Sitbon C, Barbe C, Plee J, Goeldel AL, Antonicelli F, Reguiaï Z, Jolly D, Grange F, Bernard P (2014) Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients. Dermatology 229:116–122

    Article  PubMed  Google Scholar 

  10. Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, Caux F, Marinovic B, Sinha AA, Hertl M, Bernard P, Sirois D, Cianchini G, Fairley JA, Jonkman MF, Pandya AG, Rubenstein D, Zillikens D, Payne AS, Woodley D, Zambruno G, Aoki V, Pincelli C, Diaz L, Hall RP, Meurer M, Mascaro JM Jr, Schmidt E, Shimizu H, Zone J, Swerlick R, Mimouni D, Culton D, Lipozencic J, Bince B, Grando SA, Bystryn JC, Werth VP (2012) Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 66:479–485

    Article  PubMed  Google Scholar 

  11. Patsatsi A, Kyriakou A, Pavlitou-Tsiontsi A, Giannakou A, Sotiriadis D (2012) Association of autoantibodies to BP180 with disease activity in Greek patients with bullous pemphigoid. Clin Dev Immunol 2012:854795

    Article  PubMed  PubMed Central  Google Scholar 

  12. Pfutze M, Niedermeier A, Hertl M, Eming R (2007) Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus. Eur J Dermatol 17:4–11

    PubMed  Google Scholar 

  13. Vaillant L, Bernard P, Joly P, Prost C, Labeille B, Bedane C, Arbeille B, Thomine E, Bertrand P, Lok C, Roujeau JC (1998) Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. Arch Dermatol 134:1075–1080

    Article  CAS  PubMed  Google Scholar 

  14. van Beek N, Lüttmann N, Huebner F, Recke A, Karl I, Schulze FS, Zillikens D, Schmidt E (2017) Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol 153:30–38

    Article  PubMed  Google Scholar 

  15. Wijayanti A, Zhao CY, Boettiger D, Chiang YZ, Ishii N, Hashimoto T, Murrell DF (2017) The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use? Acta Derm Venereol 96:24–31

    Article  Google Scholar 

  16. Zhao CY, Murrell DF (2015) Outcome measures for autoimmune blistering diseases. J Dermatol 42:31–36

    Article  PubMed  Google Scholar 

  17. Zhou XP, Liu B, Xu Q, Yang Y, He CX, Zuo YG, Liu YH (2016) Serum levels of immunoglobulins G1 and G4 targeting the non-collagenous 16A domain of BP180 reflect bullous pemphigoid activity and predict bad prognosis. J Dermatol 43:141–148

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The study has received a grant from Tehran University of Medical Sciences, and it is approved by the institutional review board of Tehran University of Medical Sciences. This research has been supported by Tehran University of Medical Sciences and Health Services Grant number 94-01-101-27529.

Author information

Author notes

  1. Maryam Daneshpazhooh, Maryam Ghiasi, Vahideh Lajevardi and Nafise Nasiri made equal contribution to the study.

Authors and Affiliations

  1. Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Vahdate-Eslami Square, Tehran, 11996, Iran

    Maryam Daneshpazhooh, Maryam Ghiasi, Vahideh Lajevardi, Nafise Nasiri, Kamran Balighi, Vahide Saeidi, Hamidreza Mahmoudi & Cheyda Chams-Davatchi

  2. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

    Amir Teimourpour

  3. Harvard Medical School, Boston, MA, USA

    Hasan Khosravi

Authors
  1. Maryam Daneshpazhooh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maryam Ghiasi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vahideh Lajevardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nafise Nasiri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kamran Balighi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Amir Teimourpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hasan Khosravi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vahide Saeidi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hamidreza Mahmoudi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Cheyda Chams-Davatchi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All listed authors are qualified for authorship, had access to the data, and have participated in the preparation of the manuscript.

Corresponding author

Correspondence to Maryam Daneshpazhooh.

Ethics declarations

Conflict of interest

To the authors’ knowledge, no conflict of interest, financial or other exists.

Ethical approval

The institutional review board of Tehran University of Medical Sciences has approved this study.

Informed consent

Patients gave informed consent.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Daneshpazhooh, M., Ghiasi, M., Lajevardi, V. et al. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid. Arch Dermatol Res 310, 255–259 (2018). https://doi.org/10.1007/s00403-018-1817-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-018-1817-9

Keywords

Search

Navigation